journal article·2025-04

Overcoming matrix barriers for enhanced immune infiltration using siRNA-coated metal-organic frameworks

Cheng Zeng, Xiaojing Chen, Mingxi Lin, Yizi Jin, Qing Guo, Teng Zhou, Xingang Wang, Yiping Li, Xinghui Wang, Yongming Han, Ling Du, Qianyun Tang, Peifeng Liu, Jian Zhang

Acta Biomaterialia· Volume 196
Publisher page

Abstract

The extracellular matrix (ECM) of solid tumor constitutes a formidable physical barrier that impedes immune cell infiltration, contributing to immunotherapy resistance. Breast cancer, particularly triple-negative breast cancer (TNBC), is characterized by a collagen-rich tumor microenvironment, which is associated with T cell exclusion and poor therapeutic outcomes. Discoidin domain receptor 2 (DDR2) and integrins, key ECM regulatory receptors on cancer cells, play pivotal role in maintaining this barrier. In this study, we developed a dual-receptor-targeted strategy using metal-organic frameworks (MOFs) to deliver DDR2-specific siRNA (siDDR2) and ITGAV-specific siRNA (siITGAV) to disrupt the ECM barrier. siDDR2 modulates immune infiltration by regulating collagen-cell interactions, while siITGAV suppresses TGF-β1 activation. The MOF@siDDR2+siITGAV complex significantly reduced collagen deposition, enhanced CD8+ T cell infiltration, and downregulated programmed cell death ligand 1 (PD-L1) expression in TNBC. Consequently, this approach markedly inhibited tumor growth. Our findings demonstrate that dual-receptor-targeted MOF-based nanocarriers (MOF@siDDR2+siITGAV) can effectively reprogram the tumor ECM to enhance immune cell access, offering a promising prospect for synergistic cancer immunotherapy. STATEMENT OF SIGNIFICANCE: A dual-receptor-targeted MOF nanocarrier is developed to improve immune accessibility in tumors. Concurrent blockade of DDR2 and ITGAV effectively decreases collagen deposition, increases CD8+ T cell infiltration, and suppresses PD-L1 expression. Modulating the mechanical properties of the extracellular matrix (ECM) to enhance immune accessibility offers an innovative strategy for cancer treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (54)

Show source-provided references
1. Development of immunotherapy combination strategies in cancer[J]10.1158/2159-8290.CD-20-1209 ↗
2. Immunological hallmarks of stromal cells in the tumour microenvironment[J]10.1038/nri3902 ↗
3. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion[J]10.1038/s41586-021-04057-2 ↗
4. Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation[J]10.1038/s41467-021-26352-2 ↗
5. Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma[J]10.1016/j.addr.2021.02.019 ↗
6. Targeting the microenvironment in solid tumors[J]10.1016/j.ctrv.2018.02.004 ↗
7. ECM-targeting bacteria enhance chemotherapeutic drug efficacy by lowering IFP in tumor mouse models[J]10.1016/j.jconrel.2023.02.001 ↗
8. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy[J]10.1126/sciadv.aav2437 ↗
9. Integrin αvβ6-TGFβ-SOX4 pathway drives immune evasion in triple-negative breast cancer[J]10.1016/j.ccell.2020.12.001 ↗
10. Every step of the way: integrins in cancer progression and metastasis[J]10.1038/s41568-018-0038-z ↗
11. Integrins in cancer: biological implications and therapeutic opportunities[J]10.1038/nrc2748 ↗
12. Roca-Cusachs P. Integrins as biomechanical sensors of the microenvironment[J]10.1038/s41580-019-0134-2 ↗
13. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance[J]10.1016/j.ccell.2019.01.007 ↗
14. Recent trends in cancer therapy: a review on the current state of gene delivery[J]10.1016/j.lfs.2021.119087 ↗
15. Small interfering RNA for cancer treatment: overcoming hurdles in delivery[J]10.1016/j.apsb.2020.10.005 ↗
16. Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy[J]10.3390/molecules25112692 ↗
17. Therapeutic siRNA: state of the art[J]10.1038/s41392-020-0207-x ↗
18. Delivery materials for siRNA therapeutics[J]10.1038/nmat3765 ↗
19. Rekindling RNAi therapy: materials design requirements for In vivo siRNA delivery[J]10.1002/adma.201903637 ↗
20. Lipid nanoparticle technology for clinical translation of siRNA therapeutics[J]10.1021/acs.accounts.9b00368 ↗
21. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo[J]10.1002/anie.201203263 ↗
22. siRNA delivery systems for cancer treatment[J]10.1016/j.addr.2009.04.018 ↗
23. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles[J]10.1016/j.jconrel.2018.03.012 ↗
24. Multifunctional metal-organic framework heterostructures for enhanced cancer therapy[J]10.1039/D0CS00178C ↗
25. Metal-organic framework nanoparticles[J]10.1002/adma.201800202 ↗
26. Environment-responsive lipid/siRNA nanoparticles for cancer therapy[J]10.1002/adhm.202001294 ↗
27. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape[J]10.1038/nbt.2612 ↗
28. Calcium enabled remote loading of a weak acid into pH-sensitive liposomes and augmented cytosolic delivery to cancer cells via the Proton sponge effect[J]10.1007/s11095-022-03206-0 ↗
29. Assembly and biological functions of metal-biomolecule network nanoparticles formed by metal-phosphonate coordination[J]10.1126/sciadv.ads9542 ↗
30. Mechanisms of cellular uptake and endosomal escape of calcium-siRNA nanocomplexes[J]10.1016/j.ijpharm.2016.10.009 ↗
31. Metal-phenolic coatings as a platform to trigger endosomal escape of nanoparticles[J]10.1021/acsnano.9b05521 ↗
32. Histidine-based coordinative polymers for efficient intracellular protein delivery via enhanced protein binding, cellular uptake, and endosomal escape[J]10.1039/D2BM01541B ↗
33. Metal-organic frameworks for stimuli-responsive drug delivery[J]10.1016/j.biomaterials.2019.119619 ↗
34. A review of recent developments of metal-organic frameworks as combined biomedical platforms over the past decade[J]10.1016/j.cis.2023.102908 ↗
35. A fluorescence nanoplatform for the determination of hydrogen peroxide and adenosine triphosphate via tuning of the peroxidase-like activity of CuO nanoparticle decorated UiO-66[J]10.1007/s00604-022-05170-3 ↗
36. Adenosine metabolism: emerging concepts for cancer therapy[J]10.1016/j.ccell.2019.10.007 ↗
37. ATP-triggered anticancer drug delivery[J]10.1038/ncomms4364 ↗
38. A DNA/DMXAA/metal-organic framework activator of innate immunity for boosting anticancer immunity[J]
39. Independent drug action in combination therapy: implications for precision oncology[J]10.1158/2159-8290.CD-21-0212 ↗
40. Targeting FAK in anticancer combination therapies[J]10.1038/s41568-021-00340-6 ↗
41. Integrin-mediated mechanotransduction[J]10.1083/jcb.201609037 ↗
42. Regulation of chondrocyte differentiation by the actin cytoskeleton and adhesive interactions[J]10.1002/jcp.21110 ↗
43. TGF-β: the master regulator of fibrosis[J]10.1038/nrneph.2016.48 ↗
44. Targeting TGF-β signal transduction for fibrosis and cancer therapy[J]10.1186/s12943-022-01569-x ↗
45. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression[J]10.1038/s41563-020-00849-5 ↗
46. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy[J]10.1016/j.jconrel.2012.04.045 ↗
47. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics[J]10.1038/s41571-022-00601-9 ↗
48. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors[J]10.1172/JCI45817 ↗
49. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers[J]10.1172/JCI96313 ↗
50. Profiling tumor infiltrating immune cells with CIBERSORT[J]10.1007/978-1-4939-7493-1_12 ↗
51. Zirconium: biomedical and nephrological applications[J]10.1097/MAT.0b013e3181e73f20 ↗
52. Immune modulatory properties of collagen in cancer[J]10.3389/fimmu.2021.791453 ↗
53. Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1[J]10.1016/j.molimm.2011.09.006 ↗
54. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors[J]10.1021/acsnano.9b02395 ↗